阿扎胞苷联合高三尖杉酯碱治疗老年慢性粒-单核细胞白血病的疗效和安全性分析

doi:10.3969/j.issn.1003-9198.2024.02.009

Abstract

Abstract: Objective To evaluate the efficacy and safety of azacitidine combined with homoharringtonine in the treatment of chronic myelomonocytic leukemia(CMML) in the elderly. Methods A total of 40 elderly patients with CMML in our hospital from 2018 to 2022 were enrolled in this study. The patients were divided into the experimental group and the control group according to the random number table. The experimental group received azacitidine combined with homoharringtonine, and the control group received azacitidine regimen. The efficacy and safety of the two groups were analyzed and compared. Results Thirty-six patients were enrolled, with 19 cases in the experimental group and 17 cases in the control group. The overall relieve rate(ORR) of the experimental group was higher than that of the control group(82.4% vs 52.9%, P=0.041).The adverse effects showed no statistically significant differences between the two groups(P>0.05). The median survival time of the patients in the experimental group was 33.8 months, compared with 21.2 months in the control group(P<0.05). Conclusions Azacitidine combined with homoharringtonine is safe and effective in the treatment of CMML in the elderly.

Key words: chronic myelomonocytic leukemia, aged, homoharringtonine, azacitidine

CLC Number:

R 733.7

FENG Jiangzhou, SUN Xiaoxing, JI Xiaojuan, GE Hongfeng. Analysis of efficacy and safety of azacytidine combined with homoharringtonine in treatment of chronic myelomonocytic leukemia[J]. Practical Geriatrics, 2024, 38(2): 145-148.

References

[1] PATNAIK M M, TEFFERI A.Chronic myelomonocytic leukemia:2018 update on diagnosis,risk stratification and management[J]. Am J Hematol, 2018, 93(6):824-840.
[2] 肖志坚. 骨髓增生异常综合征/骨髓增殖性肿瘤的诊断和治疗[J]. 中国实用内科杂志, 2018, 38(2): 93-97.
[3] 胡文青, 江滨. 慢性粒单核细胞白血病诊治进展[J]. 临床血液学杂志, 2019, 32(3): 242-246.
[4] LI J, HUANG Y, HOU Y, et al. High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: a single arm, phase 2 trial[J]. Front Oncol, 2022, 12: 1069246.
[5] 中华医学会血液学分会白血病淋巴瘤学组. 慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版)[J]. 中华血液学杂志, 2021, 42(1):5-9.
[6] 中华医学会血液学分会.骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J]. 中华血液学杂志, 2019, 40(2):89-97.
[7] SAVONA M R, MALCOVATI L,KOMROKJI R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms(MDS/MPN) in adults[J]. Blood, 2015, 125(12):1857-1865.
[8] ADÈS L, SEKERES M A, WOLFROMM A, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine [J]. Leuk Res, 2013, 37(6):609-613.
[9] SANTINI V, ALLIONE B, ZINI G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia[J]. Leukemia, 2017, 32(2): 413-418.
[10] ALFONSO A, MONTALBAN-BRAVO G, TAKAHASHI K, et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents[J]. Am J Hematol, 2017, 92(7): 599-606.
[11] PLEYER L, LEISCH M,KOURAKLI A, et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study[J]. Lancet Haematol, 2021, 8(2): e135-e148.
[12] ZEIDAN A M, HU X, LONG J B, et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: a large population-based study[J]. Cancer, 2017, 123(19): 3754-3762.
[13] WIJERMANS P W, RUTER B, BAER M R, et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia(CMML)[J]. Leuk Res, 2007, 32(4): 587-591.
[14] BRAUN T, ITZYKSON R, RENNEVILLE A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial[J]. Blood, 2011, 118(14): 3824-3831.
[15] FRESNO M, JIMENEZ A, VAZQUEZ D. Inhibition of translation in eukaryoticsystems byharringtonine[J]. Eur J Biochem, 1977, 72(2):323-330.
[16] KURODA J,KAMITSUJI Y,KIMURA S, et al.Anti-myeloma effect of homoharringtonine with concomitant targeting of themyeloma-promoting molecules, mcl-1, XIAP, and beta-catenin[J]. Int J Hematol, 2008, 87(5):507-515.
[17] CHEN X J, ZHANG W N, CHEN B et al.Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor[J]. Proc Natl Acad Sci U S A, 2019, 116(6):2220-2225.
[18] TONG H, REN Y, ZHANG F, et al. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells[J]. Eur J Haematol, 2008, 81(4):259-266.

Analysis of efficacy and safety of azacytidine combined with homoharringtonine in treatment of chronic myelomonocytic leukemia

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	LI Jiang, QIU Yan, WANG Ting, WANG Dan, YU Yifan, PU Lingli, BU Ling. Correlation between preoperative SII/ALB and clinicopathologic features in elderly patients with lung adenocarcinoma [J]. Practical Geriatrics, 2024, 38(9): 893-896.
[2]	DAI Jing, CUI Yan. Correlation between glycosylated hemoglobin variability and cognitive dysfunction in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(9): 931-935.
[3]	ZHENG Hong, QI Zhenbo, XU Peng, XU Jie, YU Xinyu, ZANG Yanan, ZHANG Zhaoyan. Effects of hypnotics on cognition function and daytime sleepiness in the elderly [J]. Practical Geriatrics, 2024, 38(9): 936-939.
[4]	ZHANG Xingxing, ZHANG Haiyang, HE Xiaojing, LU Xiang. Investigation on the relationship between different physical indexes and the risk of diabetes mellitus in the elderly [J]. Practical Geriatrics, 2024, 38(9): 940-943.
[5]	NI Hongyan, CHEN Yun, ZHANG Qibing, MA Yiming, XIE Chenglan. Effects of electroacupuncture on cognitive function and inflammatory factors in elderly patients undergoing lower limb orthopedic surgery during the perioperative period [J]. Practical Geriatrics, 2024, 38(9): 944-947.
[6]	LI Xiaomin, LI Xiaolin, LI Jie, WU Lei, HAO Ranran. Efficiency influencing factors of transanal double-balloon enteroscopy in elderly patients [J]. Practical Geriatrics, 2024, 38(9): 958-961.
[7]	CAI Huicui, CHEN Yan, WANG Yan, YE Jinjun, ZHU Yuying. Effects of diversified health education model with simple respiratory function exercise on cancer-related fatigue and compliance behavior in elderly patients with lung cancer receiving radiotherapy [J]. Practical Geriatrics, 2024, 38(9): 968-972.
[8]	WANG Xiaojiao, WANG Ning, CUI Hong, YE Tong, WANG Xiaoming. Influence of exercise rehabilitation in elderly patients with mild to moderate chronic heart failure [J]. Practical Geriatrics, 2024, 38(8): 775-778.
[9]	SHEN Chenjun, WANG Xiaoqing, TANG Degang, NING Ping. Correlation between standardized uric acid and renal function in elderly patients with chronic kidney disease aged 90 and over [J]. Practical Geriatrics, 2024, 38(8): 779-782.
[10]	HAO Shijie, ZOU Jianpeng, WEI Chen, LIU Qingjiang. Effect of comprehensive respiratory training on hypokinetic dysarthria in elderly patients with Parkinson’s disease [J]. Practical Geriatrics, 2024, 38(8): 783-787.
[11]	XIANG Chao, LUO Caidong. Analysis of the diagnostic value of T wave change of avL lead for the degree of coronary artery stenosis in elderly patients with coronary heart disease [J]. Practical Geriatrics, 2024, 38(8): 788-791.
[12]	LI Huiying, CAI Lili, ZHU Qiwei. Predictive value of plasma N-terminal pro-brain natriuretic peptide for prognosis in patients aged ≥80 years old with left ventricular hypertrophy [J]. Practical Geriatrics, 2024, 38(8): 797-801.
[13]	WANG Xinping, XIE Baimei, WEI Guo, YE Xiaoli, ZHAO Yayun, TAN Xiaotian. Expression levels and clinical significance of serum S100A9 and sCD163 in elderly patients with idiopathic interstitial pneumonia [J]. Practical Geriatrics, 2024, 38(8): 802-807.
[14]	LIU Meijuan, WANG Ning, WANG Dong, LU Fangzhou, LIU Juan. Effect of low-dose lidocaine combined with propofol on motor evoked potential in elderly patients undergoing intracranial tumor resection [J]. Practical Geriatrics, 2024, 38(8): 808-811.
[15]	LI Jingbing, WANG Huijun, WANG Shaoying, ZHAO Can, WANG Lidi, CAO Yujiao. Impacts of pentoxifylline combined with lipoic acid intervention on physical function and quality of life in elderly patients with frailty syndrome [J]. Practical Geriatrics, 2024, 38(8): 812-815.